10-K: Beyond Air FY 2026 Annual Report

Beyond Air reports fiscal year 2026 results, highlighting commercial progress with LungFit PH and ongoing efforts to address going concern risks.

Summary

• Reported a net loss of $34.3 million for the fiscal year ended March 31, 2026, compared to a $48.5 million loss in the prior year.
• Revenue increased to $7.7 million from $3.7 million in the previous fiscal year.
• The company's independent auditors expressed substantial doubt about the company's ability to continue as a going concern.
• LungFit PH received European CE mark approval in November 2024.
• The company is actively pursuing additional equity and debt financing to fund operations.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautious outlook due to the 'going concern' warning, recurring losses, and the need for further capital, despite the positive revenue growth and regulatory milestones.

Positives

• Revenue grew significantly to $7.7 million, more than doubling the prior year's $3.7 million.
• Achieved European CE mark approval for the LungFit PH system in November 2024.
• Successfully raised capital through multiple financing arrangements, including a $12 million note purchase and a $5 million private placement.
• Operating expenses decreased to $29.3 million from $42.9 million in the prior year, reflecting cost-management efforts.

Negatives

• The company incurred a net loss of $34.3 million for the fiscal year.
• Independent auditors included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• The company has an accumulated deficit of approximately $319.6 million as of March 31, 2026.
• The company is subject to a Discretionary Panel Monitor from Nasdaq for one year following compliance with listing standards.

Risks

• Substantial doubt regarding the ability to continue as a going concern.
• Need to raise additional capital, which may be costly, difficult to obtain, or dilutive to stockholders.
• Potential delisting from Nasdaq if compliance with the minimum bid price rule is not maintained.
• Reliance on a limited number of third-party suppliers and contract manufacturers.
• Intense competition in the medical device and biopharmaceutical markets.
• Geopolitical instability in the Middle East, particularly involving Israel, where the company has significant operations.

Future Outlook

The company expects to incur losses for the next year and anticipates that losses will decline in fiscal 2027 and 2028. Future capital needs depend on commercialization success, clinical trial outcomes, and regulatory approvals. The company plans to seek certification or regulatory approval for remaining product candidates and expects to partner with third parties for commercialization outside the U.S.

Management Comments

• Management is confident that efforts to arrange financing will enable the company to meet its obligations.
• The company intends to actively monitor the bid price of its common stock and remain in compliance with Nasdaq listing standards.

Industry Context

StockSavvy.ai notes that Beyond Air operates in a highly competitive medical device and biopharmaceutical space, facing established players like Mallinckrodt and VERO Biotech. The company's focus on nitric oxide generation from ambient air is a unique differentiator, but it faces significant regulatory and commercialization hurdles typical of early-stage medical technology firms.

Comparison to Industry Standards

• The company's reliance on third-party contract manufacturers is standard for early-stage medical device companies.
• The 'going concern' audit opinion is a common challenge for pre-profitability biotech firms in the current capital-constrained environment.
• The company's market addressable estimates for PPHN and NTM are consistent with industry-wide projections for rare respiratory disease treatments.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in various legal matters in the normal course of business but does not expect them to have a material effect on its financial position.

Related Party Transactions

• Secured loan agreement with lenders including former CEO Steven Lisi and director Robert Carey.
• Additional $2.0 million financing from director Robert Carey.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises.
• Employees and consultants are subject to the company's ongoing cost-management and restructuring efforts.
• Customers may be impacted by the company's ability to maintain supply chain stability.

Next Steps

• Demonstrate compliance with Nasdaq's minimum bid price rule by July 31, 2026.
• Continue commercialization efforts for LungFit PH in the U.S. and internationally.
• Seek discussions with the FDA in calendar year 2026 regarding the NTM clinical trial path.
• Transition fiscal year end to December 31, effective after the transition period ending December 31, 2026.

Key Dates

Recommendation

While the company has achieved regulatory milestones and revenue growth, the substantial doubt regarding its ability to continue as a going concern and the need for further dilutive financing make a 'hold' recommendation appropriate until the company demonstrates a clearer path to profitability or secures long-term funding.

Keywords

Beyond Air, XAIR, LungFit, Nitric Oxide, Medical Device, Biopharmaceutical, PPHN, 10-K